Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate
Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA Since the acquisition, the company has completed IND enabling studies and all cohorts for Phase I SAD and MAD clinical trials for its lead drug candidate In pre-clinical studies PRV-002 has demonstrated equivalent, if not superior neuroprotective effects compared to related neurosteroids, offering proof of reduced behavioral pathology associated with brain injury symptoms, easily crossing the blood-brain barrier to rapidly eliminate…